BCRX
BioCryst Pharmaceuticals Inc
8.20$
+0.6%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 1.3% | 1.8% | 1.4% | 1.6% | 2.8% | 4.7% | 3.1% | 1.7% | 1.6% | 2.4% | 449.5% | 1.8% | 76.5% | |
| 98.7% | 98.2% | 98.6% | 98.4% | 97.2% | 95.3% | 96.9% | 98.3% | 98.4% | 97.6% | -349.5% | 98.2% | 23.5% | |
| 54.0% | 75.0% | 50.1% | 34.4% | 35.1% | 37.6% | 25.6% | 26.6% | 27.8% | 10.1% | 38.6% | 23.8% | 21.0% | |
| 58.4% | 53.5% | 64.0% | 56.0% | 55.6% | 61.2% | 56.7% | 53.5% | 52.1% | 23.6% | 60.5% | 29.3% | 35.9% | |
| 112.4% | 143.9% | 114.3% | 90.4% | 90.7% | 98.8% | 82.3% | 80.1% | 79.9% | 33.6% | 99.0% | 53.1% | 56.9% | |
| -13.7% | -45.7% | -15.6% | 8.0% | 6.6% | -3.4% | 14.6% | 18.2% | 18.6% | 64.0% | -448.6% | 45.1% | -33.3% | |
| 31.5% | 26.3% | 26.4% | 22.6% | 21.2% | 18.6% | 16.1% | 13.2% | 12.3% | 3.5% | 12.6% | 9.9% | 8.0% | |
| -41.3% | -67.6% | -37.7% | -11.4% | -11.5% | -19.8% | 0.5% | 4.0% | 7.6% | 61.0% | -460.8% | 36.4% | -40.5% | |
| 0.4% | -1.5% | 0.4% | 0.2% | 0.5% | 0.6% | 0.5% | 0.9% | -0.5% | 0.5% | 0.6% | 0.5% | 0.4% | |
| -41.7% | -66.1% | -38.1% | -11.6% | -12.0% | -20.4% | 0.0% | 3.1% | 8.1% | 60.5% | -461.5% | 35.9% | -40.9% | |
| -9.3% | -40.9% | -11.0% | 11.5% | 10.0% | -0.9% | 16.9% | 17.4% | 20.2% | 65.5% | -447.5% | 45.3% | -32.2% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.